Document:

<PAGE>

                                                            Exhibit 10(uu)

                          STOCK PURCHASE AGREEMENT

             This Stock Purchase Agreement (this "Agreement") is made and
entered into as of April 18, 2002, by and between FEMMEPHARMA, INC., a
Pennsylvania corporation ("FemmePharma") whose address is 37 West Avenue,
Suite 101, Wayne, Pennsylvania 19087, and KV PHARMACEUTICAL COMPANY ("KV"),
2503 S. Hanley Rd., St. Louis, Missouri 63144.

1.       CONTEMPORANEOUS PRODUCT LICENSE AGREEMENT; DUE DILIGENCE REVIEW.
         ---------------------------------------------------------------

             1.1. On or about the date of this Agreement, FemmePharma
and KV have entered into a license agreement (the "License Agreement") under
which FemmePharma has granted KV marketing rights relating to a Danazol
containing product, all as more fully set forth in the License Agreement
(the "Danazol Product"). The Product is to be manufactured and sold under
certain technology which is the subject of U.S. Patent #5,993,856 and U.S.
Patent Application 09-355,213 filed June 27, 1999 (the "Patent") owned by
FemmePharma (as defined in the License Agreement, the "Technology").

2.       PURCHASE AND SALE OF SHARES.
         ---------------------------

             2.1. SALE AND ISSUANCE OF INITIAL SHARES - INITIAL CLOSING.

                  (a) Subject to the terms and conditions of this Agreement,
KV agrees to purchase from FemmePharma, and FemmePharma agrees to issue and
sell to KV 34,965 shares (the "INITIAL SHARES") of Series C Preferred Stock
of FemmePharma, which shall be issued pursuant to the Designation Statement
attached hereto as Exhibit A ("Series C Stock"), for an aggregate purchase
                   ---------
price of Two Million Dollars ($2,000,000), or a price per share of $57.20
(the "Per Share Price").

                  (b) The closing of the purchase and sale of the Initial
Shares (the "INITIAL CLOSING") shall take place by teleconference call and
telecopier on the date of this Agreement (the "Initial Closing Date").

                  (c) At the Initial Closing FemmePharma shall deliver to KV:

                      (i)   a stock certificate representing the Initial
Shares being purchased by KV;

                      (ii)  an Amended and Restated Stockholders Agreement
in the form of Exhibit B hereto (the "Stockholders Agreement") duly executed
               ---------
by all of the parties thereto other than KV; and

                      (iii) a Registration Rights Agreement in the form
of Exhibit C hereto (the "Registration Rights Agreement") duly executed by
   ---------
all of the parties thereto other than KV.

                  (d) If the issuance and sale of the Initial Shares is not
consummated at the Initial Closing, either party not then in breach of this
Agreement can terminate this Agreement by written notice to the other party
of its election to so terminate.

<PAGE>
<PAGE>

                  (e) At the Initial Closing KV shall deliver to
FemmePharma:

                      (i)   the purchase price for the Initial Shares by
wire transfer in accordance with wire transfer instructions which shall be
furnished to KV by FemmePharma prior to the Closing;

                      (ii)  the Stockholders Agreement duly executed by
KV; and

                      (iii) the Registration Rights Agreement duly executed
by KV.

             2.2. SALE AND ISSUANCE OF SUBSEQUENT SHARES - SECOND CLOSING.

                  (a) Subject to the terms and conditions set forth herein,
at a second closing (the "Second Closing") which shall be held on a date and
time mutually agreed to by FemmePharma and KV not later than fifteen (15)
business days following the commencement of the Phase III Studies, as
contemplated by the License Agreement, and provided that the License
Agreement remains in effect, KV agrees to purchase from FemmePharma, and
FemmePharma agrees to issue and sell to KV, 52,447.5 shares of Series C
Stock (the "SECOND CLOSING SHARES") at the Per Share Price, for an aggregate
purchase price of Three Million Dollars ($3,000,000). Conversely, this
Agreement shall automatically terminate and be of no further force or effect
if and upon the termination of the Danazol Product from the License
Agreement prior to the Second Closing.

                  (b) The purchase and sale of the Second Closing Shares
shall take place in person or by teleconference call and telecopier at the
offices of Morgan, Lewis & Bockius or other location mutually acceptable to
the parties.

                  (c) At the Second Closing, FemmePharma shall deliver to KV
a stock certificate representing the Second Closing Shares.

                  (d) At the Second Closing KV shall deliver the purchase
price for the Second Closing Shares by wire transfer in accordance with wire
transfer instructions which shall be furnished to KV by FemmePharma at least
three business days prior to the Second Closing.

3.       REPRESENTATIONS AND WARRANTIES OF KV.
         ------------------------------------

             KV hereby represents and warrants to, and agrees with,
FemmePharma as follows:

             3.1. KV is duly authorized to execute this Agreement, and
this Agreement constitutes the legal, valid and binding obligation of KV
enforceable against KV in accordance with its terms, except as such
enforcement may be limited by applicable laws relating to creditors' rights
or principles of equity affecting the availability of remedies.

             3.2. KV will acquire the Series C Stock for its own
account for investment and not with a view to the sale or distribution
thereof or the granting of any participation therein, and has no present
intention of distributing or selling to others any of such interest or
granting any participation therein.

                                    -2-

<PAGE>
<PAGE>

             3.3. KV has such knowledge and experience in finance,
securities, investments and other business matters so as to be able to
protect the interests of KV in connection with its purchase of the Series C
Stock. KV is aware that an investment in the Series C Stock is speculative
and subject to substantial risks. KV has no present or contemplated future
need to dispose of any of the Series C Stock and is capable of bearing the
economic risks of an investment in the Series C Stock, including, but not
limited to, the possibility of the complete loss of the purchase price of
the Series C Stock and the limited transferability of the Series C Stock,
which may make the liquidation of its investment impossible for the
indefinite future.

             3.4. KV acknowledges that no market exists for the Series
C Stock, that it is unlikely that a market will develop in the foreseeable
future, and that KV may find it impossible to liquidate its investment at a
time when it may desire to do so, or at any other time.

             3.5. KV has been advised by FemmePharma that none of the
Series C Stock to be issued to KV, or any stock or securities in which it
may hereafter be converted, will be registered under the Securities Act of
1933 (the "Act"), that the Series C Stock, or any stock or securities in
which it may hereafter be converted, will be issued on the basis of the
statutory exemptions provided by Section 4(2) of the Act and/or Regulation D
thereunder relating to transactions by an issuer not involving any public
offering and under similar exemptions under certain state securities laws,
that this transaction has not been reviewed by, passed upon or submitted to
any federal or state agency or self-regulatory organization where an
exemption is being relied on; and that FemmePharma's reliance thereon is
based in part upon the representations made by KV in this Agreement. KV
acknowledges that KV has been informed by FemmePharma of, or is otherwise
familiar with, the nature of the limitations imposed by the Act and the
rules and regulations thereunder on the transfer of the Series C Stock. In
particular, KV agrees that no sale, assignment or transfer of any of the
Series C Stock or any stock or securities in which it may hereafter be
converted, shall be valid or effective, and FemmePharma shall not be
required to give any effect to such sale, assignment or transfer, in the
absence of: (i) the sale, assignment or transfer of the Series C Stock or
any stock or securities in which it may hereafter be converted, is
registered under the Act, it being understood that the Series C Stock or any
stock or securities in which it may hereafter be converted, is not currently
registered for sale and that FemmePharma has no obligation or intention to
so register the Series C Stock (except as provided in Article 6), (ii) the
shares of Series C Stock are sold, assigned or transferred in accordance
with all of the requirements and limitations of Rule 144 of the Act, it
being understood that Rule 144 is not available at the present time for the
sale of the Series C Stock, or (iii) such sale, assignment or transfer is
otherwise exempt from registration under the Act. KV further understands
that an opinion of counsel and other documents shall be required to transfer
the Series C Stock. KV acknowledges that the Series C Stock shall be subject
to a stop transfer order and the certificate or certificates evidencing
shares of the Series C Stock shall bear the following or a substantially
similar legend or other legend as may appear on the forms of stock
certificates and such other legends as may be required by state securities
laws:

             "The shares represented by this certificate have not been
         registered under the Securities Act of 1933, as amended (the
         "Act"), or any state securities laws and neither such shares nor
         any interest therein may be offered, sold, pledged, assigned or
         otherwise transferred in the absence of: (i) a registration
         statement with respect thereto is effective under the Act and any
         applicable state securities laws or (ii) the issuer of the shares
         receives an opinion of counsel to the holder of such shares,

                                    -3-

<PAGE>
<PAGE>

         which counsel and opinion are reasonably satisfactory to the issuer,
         that such shares may be offered, sold, pledged, assigned or transferred
         in the manner contemplated without an effective registration
         statement under the Act or applicable state securities laws."

             3.6. During the negotiation of the transactions contemplated
herein, KV and KV's representatives and legal counsel have been
afforded access to corporate books, financial statements, records,
contracts, documents and other information concerning FemmePharma and to its
offices and facilities, have been afforded an opportunity to ask such
questions of FemmePharma's officers, employees, agents, counsel, accountants
and representatives concerning FemmePharma's business, operations, financial
condition, assets, liabilities and other relevant matters as they have
deemed necessary or desirable, and have been given all such information as
has been requested, in order to evaluate the merits and risks of the
prospective investments contemplated herein. In taking any action or
performing any role relative to the arranging of the proposed investment, KV
has acted solely in KV's own interest, and neither KV nor any agents or
employees of KV has acted as an agent of FemmePharma. KV acknowledges that
it has no assurances that the forecasts in the Business Plan provided to KV
by FemmePharma in connection with the Due Diligence Review will be the same
as the actual results achieved by FemmePharma.

4.       REPRESENTATIONS AND WARRANTIES OF FEMMEPHARMA.
         ---------------------------------------------

             In order to induce KV to enter into this Agreement,
FemmePharma represents and warrants to KV that, except as disclosed in the
Disclosure Statement attached hereto, the statements contained in this
Article 4 are true and correct as of the date hereof.

             4.1. FemmePharma is a corporation duly organized, validly
existing and in good standing under the laws of the Commonwealth of
Pennsylvania, with full corporate power and authority to own, lease, use and
operate its properties and to conduct its business as and where now owned,
leased, used, operated and conducted.

             4.2. FemmePharma does not own, directly or indirectly, any
equity or other ownership interest in any corporation, partnership, joint
venture or other entity or enterprise. FemmePharma is not subject to any
obligation or requirement to provide funds to or make any investment (in the
form of a loan, capital contribution, guarantee or otherwise) in any other
person or entity.

             4.3. FemmePharma has provided KV with information related
to the Danazol Product (including its formulation and delivery method), the
Technology, the Patent, related clinical information (including the results
of a primate study conducted by FemmePharma), the market for the Danazol
Product, FemmePharma's business, business plans, financial condition,
results of operation and projections therefor, and such other information as
has been requested by KV in connection with the License Agreement and KV's
proposed investment in FemmePharma contemplated by this Agreement. The
information provided also included complete and accurate copies of the
written information provided to certain independent investors (the
"Independent Investors") by FemmePharma in connection with the investment by
the Independent Investors in FemmePharma on or about November 13, 2000, and
December 29, 2000, respectively, in an aggregate amount of $700,000 and
$750,000, respectively (the "Independent Investor

                                    -4-

<PAGE>
<PAGE>

Investments") under agreements with the Independent Investors for the
Independent Investor Investments (the "Independent Investor Agreements").
The execution and delivery of the Independent Investors Agreements and the
consummation of the transactions contemplated thereby were duly authorized
by the Board of Directors of FemmePharma. The Independent Investor
Agreements were duly executed and delivered by FemmePharma and constitute
the legal, valid and binding obligation of FemmePharma, enforceable against
it in accordance with its terms, except as such enforcement may be limited
by applicable laws relating to creditors' rights or principles of equity
affecting the availability of remedies.

             4.4. FemmePharma has all of the corporate power and
authority required to enter into this Agreement and to complete the
transactions contemplated by this Agreement. The execution and delivery of
this Agreement and the consummation of the transactions contemplated hereby
have been duly authorized by the Board of Directors and, if necessary, the
shareholders of FemmePharma. This Agreement has been duly executed and
delivered by FemmePharma and constitutes the legal, valid and binding
obligation of FemmePharma, enforceable against it in accordance with its
terms, except as such enforcement may be limited by applicable laws relating
to creditors' rights or principles of equity affecting the availability of
remedies.

             4.5. (a) (i)   FemmePharma's authorized capital stock
consists solely of: (A) 19,000,000 shares of Common Stock, no par value, of
which 1,429,379 shares are issued and outstanding, Management Options (the
"Management Options") are outstanding for the purchase of 925,823 shares and
Warrants (the "Warrants") are outstanding for the purchase of 200,000
shares, and (B) 2,000,000 shares of Preferred Stock, no par value, of which:
(x) 713,500 shares are designated Series A Preferred Stock (and 713,375
shares are issued and outstanding), (y) 713,500 shares are designated Series
B Preferred Stock (and 713,500 shares are issued and outstanding), and (z)
130,000 shares are designated Series C Preferred Stock, no par value (none
of which shares are issued and outstanding). The registered shareholders of
the currently outstanding Common Stock and Preferred Stock and the holders
of the issued and outstanding Management Options and Warrants are as set
forth in Schedule 4.5. Gerianne M. DiPiano ("DiPiano") owns the shares of
         ------------
Common Stock shown to be owned by her in Schedule 4.5, free and clear of all
                                         ------------
pledges, liens or encumbrances and such shares are not subject to any
agreement regarding the sale, transfer or voting thereof.

                      (ii)  No shares of capital stock of FemmePharma
have been issued and are held in its treasury.

                      (iii) Except for the shares of Common Stock
reserved for the conversion of the Preferred Stock purchased by the
Independent Investors and upon the exercise of the Management Options and
the Warrants, and the shares of Common Stock reserved for issuance upon the
conversion of shares of Series C Stock issuable pursuant to this Agreement
(including shares of Series C Stock which may be issued in respect of
dividend payments), no shares of Common Stock have been reserved for
issuance upon the exercise of stock purchase options or any other rights to
purchase Common Stock or otherwise promised to be issued or sold. The
issuance of all of such shares of Common Stock that are so issuable has been
duly authorized, and such shares have been duly reserved for issuance, by
the Board of Directors of FemmePharma.

                                    -5-

<PAGE>
<PAGE>

                      (iv)  Each outstanding share of FemmePharma Common
Stock is duly authorized and validly issued, fully paid and non-assessable,
and has not been issued in violation of any preemptive rights, rights of
first refusal or similar rights.

                  (b) FemmePharma has paid no cash dividends on any Common
Stock and has entered into no agreement for the payment of any future
dividends.

                  (c) FemmePharma knows of no agreements among the holders
of the Common Stock which limit or control the manner in which the parties
thereto vote their Common Stock.

             4.6. Upon the payment by KV of the Per Share Price for the
Series C Stock to be purchased by KV and the issuance and delivery of such
shares of Series C Stock to KV by FemmePharma contemplated hereunder, all of
such shares of Series C Stock will be duly authorized, validly issued, fully
paid and non-assessable, and no further governmental authorization or
approval of FemmePharma is or will be required in connection with the
issuance thereof.

             4.7. Neither the execution and delivery of this Agreement
by FemmePharma, nor the completion of the transactions contemplated hereby
by FemmePharma, will:

                      (i)   Conflict with or result in a breach of the
Articles of Incorporation or Bylaws of FemmePharma;

                      (ii)  Violate, or conflict with, or result in a
breach of any provision of, or constitute a default (or an event which, with
the giving of notice, the passage of time or otherwise, would constitute a
default) under, or entitle any party (with the giving of notice, the passage
of time or otherwise) to terminate, accelerate or call a default under, or
result in the creation of any encumbrance upon any of the properties or
assets of FemmePharma under, any of the terms or conditions of any note,
bond, mortgage, indenture, deed of trust, license, contract, undertaking,
agreement, lease or other instrument or obligation to which FemmePharma is a
party or by which it or its assets are bound or subject;

                      (iii) Violate any law applicable to FemmePharma
or any of its assets; or

                      (iv)  Require any action or consent or approval
of, or review by, or registration or filing by FemmePharma with, any third
party or any governmental authority.

             4.8. The books of account and financial records of
FemmePharma are currently maintained on a cash basis and fairly reflect the
assets and liabilities of FemmePharma on a cash basis, but do not include
accruals for any items of income or expense, and the Income and Expense
Statements and balance sheets for the years ended December 31, 2000 and
December 31, 2001, respectively, provided to KV by FemmePharma fairly
present the financial condition, assets and liabilities of FemmePharma as at
the respective dates and the results of its operations and cash flows for
the periods covered thereby. FemmePharma has provided to KV projections of
its future business and results of operation for 2002 (the "Projections").
FemmePharma has used its current knowledge in preparing the Projections;
however, there is no assurance that the Projections will be achieved by
FemmePharma. FemmePharma owns all of its assets free and clear of all liens,
claims and encumbrances.

                                    -6-

<PAGE>
<PAGE>

             4.9.  Since December 31, 2000, FemmePharma has conducted
its business in the ordinary course, consistent with past practice, and, to
its knowledge, there has been no material adverse change in the assets,
liabilities, results of operation, prospects, business or financial
condition of FemmePharma, or any event, occurrence or development which may
reasonably be expected to result in such a change or which would adversely
affect the ability of FemmePharma to consummate the transactions
contemplated hereby; provided, that since December 31, 2000 FemmePharma's
financial condition has deteriorated due to continued operations without
revenues.

             4.10. FemmePharma maintains and operates a single location
for the conduct of its business in the Commonwealth of Pennsylvania and is
licensed to transact business in the states set forth in Schedule 4.10.
                                                         -------------
FemmePharma has all licenses, permits, authorizations and administrative
approvals ("Authorizations") required for the conduct of its business in
each state in which FemmePharma conducts its business, except where the
failure to have any such Authorization would not have a material adverse
effect on FemmePharma or the business conducted by FemmePharma. FemmePharma
is in compliance, in all material respects, with all laws, regulations and
orders applicable to it or to the conduct or operation of its business or
the ownership or use of its assets.

             4.11. There are no legal proceedings pending or, to the
knowledge of FemmePharma, threatened against FemmePharma or its assets.

             4.12. Schedule 4.12 contains a list of all material
                   -------------
trademarks, trade names, copyrights, patents and other intellectual property
assets owned by FemmePharma, except for licenses implied by the sale of a
product and perpetual, paid-up licenses for commonly available software
programs under which FemmePharma is the licensee ("FemmePharma's
Intellectual Property"). There are no outstanding or, to the knowledge of
FemmePharma, threatened disputes or disagreements with respect to any such
intellectual property assets. To its knowledge, none of FemmePharma's
Intellectual Property infringes or is alleged to infringe the intellectual
property rights of any other person.

             4.13. FemmePharma has filed or caused to be filed on a
timely basis all tax returns and reports which have been required to be
filed by FemmePharma and has paid or made provision for the payment, when
due, of all taxes payable by FemmePharma pursuant thereto or otherwise, the
failure of which would have a material adverse affect on FemmePharma.

             4.14. FemmePharma has no obligation or liability to any
broker, finder or agent in connection with the License Agreement or this
Agreement.

5.       INDEMNIFICATION.
         ---------------

             5.1.  By KV. KV agrees to indemnify, defend and hold
                   -----
harmless FemmePharma and each officer, director, partner, employee, agent
and controlling person of FemmePharma, past, present or future, from and
against any and all loss, damage or liability due to or arising out of a
breach of any representation or warranty made by KV in Article 3 hereof.

             5.2.  By FemmePharma. FemmePharma agrees to indemnify,
                   --------------
defend and hold harmless KV and each officer, director, partner, employee,
agent and controlling person of KV,

                                    -7-

<PAGE>
<PAGE>

past, present or future, from and against any and all loss, damage or
liability due to or arising out of a breach of any representation or
warranty of FemmePharma made in Article 4 hereof.

6.       COVENANT OF FEMMEPHARMA.
         -----------------------

             6.1. FemmePharma covenants and agrees with KV that
subsequent to the closing of the transactions contemplated by this Agreement
(the "Closing"), FemmePharma will provide KV with a copy of FemmePharma's
financial statements, including a balance sheet, income statement and
statement of cash flows, prepared in accordance with generally accepted
accounting principles (GAAP), consistently applied from period to period,
for each of the first three fiscal quarters of FemmePharma not later than 30
days after the end of each such quarter and for each fiscal year of
FemmePharma not later than 75 days after the end of the fiscal year. If the
financial statements of FemmePharma for the fiscal year are audited,
FemmePharma shall provide KV with a copy of such audited financial
statements and of the auditors' opinion related thereto. In addition,
FemmePharma shall provide KV or a representative of KV; (i) reasonable
access from time to time (but not necessarily more often than quarterly
following the receipt of such financial statements) during normal business
hours to the chief executive officer and chief financial officer of
FemmePharma in order to keep KV informed of and to review the status of
FemmePharma's business, results of operation and financial condition; and
(ii) such additional access to FemmePharma's records as is necessary to
allow KV to comply with requirements of any applicable law or administrative
or regulatory requirement applicable to KV; provided that, any such
information shall be held by KV in confidence and not used or disclosed by
KV except to the extent it is legally compelled to do so. In addition,
FemmePharma shall provide KV with a copy of all notices and other
communications by FemmePharma with the holders of its common stock
generally. This covenant shall terminate at the earlier of such time as: (a)
FemmePharma has a public offering of securities registered under the
Securities Act of 1933; provided, however, that FemmePharma will continue
thereafter to provide KV copies of such financial information at such times
as are required by KV to comply with applicable securities laws, or (b) KV
no longer owns any shares of Series C Stock or Common Stock of FemmePharma.

7.       CONDITIONS PRECEDENT TO KV'S OBLIGATION TO CLOSE.
         ------------------------------------------------

             KV's obligation to purchase the Series C Stock and to take
any other actions required to be taken by KV at either the Initial Closing
or the Second Closing is subject to the satisfaction, at or prior to the
applicable Closing, of each of the following conditions (any of which may be
waived by KV, in whole or in part):

             7.1. Accuracy of Representations. The representations and
                  ---------------------------
warranties of FemmePharma in this Agreement shall have been accurate as of
the date of this Agreement and shall continue to be accurate as of the
Closing Date as if made on the Closing Date, and FemmePharma shall have
delivered to KV at the Closing a Certificate that such representations and
warranties are true and correct on the Closing Date.

             7.2. No Proceedings. There shall not be outstanding or
                  --------------
then threatened against FemmePharma or KV any proceeding by a third party:
(a) involving any challenge to, or seeking damages or other relief in
connection with, any of the transactions contemplated by this Agreement

                                    -8-

<PAGE>
<PAGE>

or the License Agreement, or (b) that prevents, delays, makes illegal or
otherwise interferes with the sale and delivery of the Series C Stock
contemplated hereby.

             7.3. License Agreement. The License Agreement shall have
                  -----------------
been entered into by FemmePharma and KV and shall be in full force and
effect, and FemmePharma shall not be in breach thereof.

             7.4. Second Closing. With respect to the Second Closing,
                  --------------
(i) the Initial Closing shall have been consummated, and (ii) the Phase III
Studies shall have commenced pursuant to and as defined in the License
Agreement.

             7.5. Performance. FemmePharma shall have performed all of
                  -----------
the covenants required by this Agreement to be performed by it on or before
the Closing.

8.       CONDITIONS PRECEDENT TO FEMMEPHARMA'S OBLIGATION TO CLOSE.
         ---------------------------------------------------------

             FemmePharma's obligation to sell the Series C Stock to KV
hereunder and to take the other actions required to be taken by FemmePharma
at either the Initial Closing or the Second Closing is subject to the
satisfaction, at or prior to such Closing, of each of the following
conditions (any of which may be waived by FemmePharma in whole or in part):

             8.1. Accuracy of Representations. KV's representations and
                  ---------------------------
warranties in this Agreement shall have been accurate as of the date of this
Agreement and as of the Closing Date as if made on the Closing Date, and KV
shall have delivered to FemmePharma at the Closing a certificate that such
representations and warranties are true and correct on the Closing Date

             8.2. KV's Performance. The covenants and obligations that
                  ----------------
KV is required to perform or to comply with pursuant to this Agreement at or
prior to the Closing shall have been performed and complied with.

             8.3. No Proceedings. There shall not be outstanding or
                  --------------
then threatened against FemmePharma or KV any proceeding: (a) involving any
challenge to, or seeking damages or other relief in connection with, any of
the transactions contemplated by this Agreement or the License Agreement, or
(b) that prevents, delays, makes illegal or otherwise interferes with the
sale and delivery of the Series C Stock contemplated hereby.

             8.4. License Agreement. The License Agreement shall have
                  -----------------
been entered into by FemmePharma and KV and shall be in full force and
effect, and KV shall not be in breach thereof.

             8.5. Second Closing. With respect to the Second Closing,
                  --------------
(i) the Initial Closing shall have been consummated, and (ii) the License
Agreement shall not have been terminated with respect to the Danazol
Product.

             8.6. Performance. KV shall have performed all of the
                  -----------
covenants required by this Agreement to be performed by it on or before the
Closing.

                                    -9-

<PAGE>
<PAGE>

9.       MISCELLANEOUS PROVISIONS.
         ------------------------

             9.1. All warranties, representations, indemnities and
agreements hereunder shall survive any termination or revocation of this
Agreement for a period of two years.

             9.2. Should any one or more of the provisions of this
Agreement be determined by a judicial or administrative authority having
jurisdiction thereof to be illegal or unenforceable, such illegal or
unenforceable provisions shall be so modified by the authority making such
determination, if and to the extent possible, so as to give effect to the
intentions of the parties expressed herein, and all other provisions of this
Agreement shall be given effect separately from the provision or provisions
determined to be illegal or unenforceable and shall not be affected thereby.

             9.3. Except as otherwise provided herein, all the terms,
provisions, representations and warranties of this Agreement shall be
binding upon, inure to the benefit of, and be enforceable by the respective
successors and assigns of the parties hereto.

             9.4. It is the intention of the parties hereto that the
laws of Pennsylvania should govern the validity of this Agreement, the
construction of its terms and the interpretation of the rights and duties of
the parties hereto, without regard to conflict or choice of law principles.

             9.5. This Agreement contains the entire agreement between
the parties hereto relating to the sale by FemmePharma and purchase by KV of
the Series C Stock and may be amended only by a written amendment signed by
all the parties hereto.

             9.6. No failure or delay of any party hereto in exercising
any right, power or privilege hereunder shall operate as a waiver thereof,
nor shall any single or partial exercise thereof preclude any other or
further exercise thereof or the exercise of any other right, power or
privilege.

             9.7. The rights and remedies herein provided shall be
cumulative and not exclusive of any other rights or remedies provided by law
or otherwise.

             9.8. All notices, requests, consents, and other
communications required or permitted hereunder shall be in writing and shall
be delivered, or mailed first class postage prepaid, Express, registered or
certified mail, or sent by prepaid next business day courier:

                  (i)  If to FemmePharma at the address set forth for
FemmePharma at the beginning of this Agreement;

                  (ii) If to KV at the address set forth for KV at
the beginning of this Agreement;

or such other address as to which FemmePharma, or KV shall have specified by
written notice to the other in accordance with this Section 9.8; and such
notices and other communications shall for all purposes of this Agreement be
treated as being effective or having been given when delivered, if delivered
personally, or, if sent by mail, at the earlier of their receipt or 72 hours
after the same have been deposited in the United States Mail, addressed and
postage prepaid as aforesaid, or if

                                    -10-

<PAGE>
<PAGE>

sent by prepaid next business day courier on the business day following
delivery thereof to the courier.

             9.9.  This Agreement may be executed in two or more
counterparts with the same effect as if all parties hereto had signed the
same documents. All such counterparts shall be deemed an original, shall be
construed together and shall be considered one and the same instrument.
Facsimile signatures shall be as effective as original signatures hereto.

             9.10. Copies of this Agreement which are true copies of
the original and are manually signed by the parties shall be deemed
duplicate originals.

         IN WITNESS WHEREOF, the parties hereto have caused this Agreement
to be signed on the date and year first above written.

                                        FEMMEPHARMA, INC.

                                        By: /s/ Gerianne M. DiPiano
                                           ------------------------------
                                              Gerianne M. DiPiano
                                              President

                                        KV PHARMACEUTICAL COMPANY

                                        By: /s/ Alan G. Johnson
                                           -------------------------------
                                              Alan G. Johnson
                                              Senior Vice President

                                    -11-<PAGE>

                                                              Exhibit 10(vv)

                                                            [Execution Copy]

                        PRODUCT ACQUISITION AGREEMENT

         This Product Acquisition Agreement (this "Agreement") is made and
                                                   ---------
entered into as of March 31, 2003, by and among Schwarz Pharma
Manufacturing, Inc., an Indiana corporation ("SPM"), 1101 "C" Avenue West,
                                              ---
Seymour, Indiana 47274, SRZ Properties, Inc., a Delaware corporation ("SRZ"
                                                                       ---
and, together with SPM, "Schwarz"), 1101 "C" Avenue West, Seymour, Indiana
                         -------
47274, and KV Pharmaceutical Company, a Delaware corporation ( "KV"), 2503
                                                                --
S. Hanley Road, St. Louis, Missouri 63144.

                            W I T N E S S E T H:
                            - - - - - - - - - -

         WHEREAS, KV desires to purchase, and Schwarz desires to sell,
Schwarz's Niferex(R) product line, subject to the terms and conditions set
forth herein.

         NOW, THEREFORE, in consideration of the mutual covenants and
agreements contained herein and other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, Schwarz and KV
agree as follows:

1.       CERTAIN TERMS.

         1.1.  Definitions. The terms defined in Schedule 1.1, when used
               -----------                       ------------
in this Agreement, shall have the meanings set forth therein.

         1.2.  Terminology. All section, subsection, schedule, appendix
               -----------
and exhibit references used in this Agreement are to this Agreement unless
otherwise specified. All schedules and exhibits attached to this Agreement
constitute an integral part of this Agreement and are incorporated herein.
Unless the context of this Agreement clearly requires otherwise, (a) the
singular shall include the plural and the plural shall include the singular
wherever and as often as may be appropriate, (b) the masculine shall include
the feminine and the feminine shall include the masculine wherever or as
often as may be appropriate, (c) the words "include" and "including" shall
mean "including without limitation" and (d) the words "hereof," "herein,"
"hereunder," and similar terms in this Agreement shall refer to this
Agreement as a whole and not any particular section or article in which such
words appear.

2.       ACQUISITION OF PRODUCTS.

         2.1.  Sale of Assets. Upon the terms and subject to the conditions
               --------------
of this Agreement, (i) Schwarz shall sell, assign, transfer and deliver to
KV or its designee at Closing, free and clear of all encumbrances (other
than encumbrances created in connection with any Transaction Document), all
of Schwarz's right, title and interest in the Assets (subject to Assumed
Liabilities but excluding all Excluded Assets and Excluded Liabilities) and
the Inventory and (ii) KV or its designee shall purchase and accept all of
Schwarz's right, title and interest in the Assets (subject to Assumed
Liabilities but excluding all Excluded Assets and Excluded Liabilities) and
Inventory from Schwarz.

<PAGE>
<PAGE>

         2.2.  Assumption of Liabilities. With respect to the purchase
               -------------------------
and sale of the Assets, KV will, in addition to payment of the Purchase
Price, assume at the Closing and subsequently, in due course, pay, honor and
discharge, the Assumed Liabilities.

3.       CONSIDERATION; ALLOCATION OF PURCHASE PRICE.

         3.1.  Purchase Price. In consideration of the sale of the Assets
               --------------
hereunder at the Closing, KV shall pay Schwarz at the Closing the sum of
$14,300,000 (the "Purchase Price") plus the Inventory Price. Payment of the
                  --------------
Purchase Price and the Inventory Price shall be made by wire transfer of
immediately available funds in accordance with the Wire Transfer
Instructions.

         3.2.  Inventory. The Inventory Price shall be determined by
               ---------
multiplying (i) the amount of finished Product units included in Schwarz's
inventory on the Closing Date (the "Inventory") by (ii) the applicable price
                                    ---------
therefor set forth on Schedule 3.2 hereto.
                      ------------

         3.3.  Tax Reporting and Allocation of Consideration. KV and
               ---------------------------------------------
Schwarz recognize their mutual obligations pursuant to Section 1060 of the
Code to timely file IRS Form 8594 (the "Asset Acquisition Statement") with
                                        ---------------------------
each of their respective federal income tax returns.

4.       CLOSING.

         4.1   The Closing. The closing of the sale and purchase of the
               -----------
Assets (the "Closing") shall take place on the date of this Agreement (the
             -------
"Closing Date") by teleconference call and facsimile. At the Closing, the
 ------------
Parties to this Agreement will exchange the funds, certificates and other
documents specified in this Agreement. The Closing shall be deemed to have
occurred at 11:59 PM EST on the Closing Date.

         4.2.  Proceedings at Closing. All proceedings to be taken and
               ----------------------
all documents to be executed and delivered by Schwarz in connection with the
consummation of the transactions contemplated hereby shall be reasonably
satisfactory in form and substance to KV and its counsel. All proceedings to
be taken and all documents to be executed and delivered by KV in connection
with the consummation of the transactions contemplated hereby shall be
reasonably satisfactory in form and substance to Schwarz and its counsel.
All proceedings to be taken and all documents to be executed and delivered
by all parties at the Closing shall be deemed to have been taken, executed
and delivered simultaneously, and no proceedings shall be deemed taken nor
any documents executed or delivered until all have been taken, executed and
delivered.

         4.3.  Deliveries by Schwarz at the Closing. At the Closing,
               ------------------------------------
Schwarz shall deliver to KV the following:

               (a) a receipt for the Purchase Price and the Inventory Price;

               (b) the Trademark Transfer Agreement, duly executed on behalf
of SPM, SRZ and Schwarz Pharma, Inc.;

                                     2

<PAGE>
<PAGE>

               (c) certified copies of the resolutions of the Boards of
Directors of each of SPM and SRZ approving this Agreement, the other
Transaction Documents and the transactions contemplated hereby and thereby;
and

               (d) such other instruments and documents, in form and
substance reasonably acceptable to KV, as may be reasonably necessary to
effect the Closing.

         4.4.  Deliveries by KV at the Closing. At the Closing, KV shall
               -------------------------------
deliver to Schwarz the following:

               (a) the Purchase Price and the Inventory Price, as provided in
Section 3.1;
-----------

               (b) the Assumption Agreement, duly executed on behalf of KV;

               (c) a certified copy of the resolutions of the Board of
Directors of KV approving this Agreement, the other Transaction Documents to
which it is a party and the transactions contemplated hereby and thereby;
and

               (d) such other instruments and documents, in form and
substance reasonably acceptable to Schwarz, as may be reasonably necessary
to effect the Closing.

5.       COVENANTS AND AGREEMENTS.

         5.1.  Limited License. Schwarz hereby grants to KV a non-exclusive,
               ---------------
non-transferable, royalty-free license (the "License") to use Schwarz's
                                             -------
existing NDC(s) for each of the Products to the extent such NDC(s) are
applied to the existing packaging and labeling of the Inventory and the
Products supplied to KV pursuant to Section 5.6. The License shall
                                    -----------
automatically expire upon the earlier to occur of (i) the date on which KV
sells all of the Inventory and (ii) the date that is 180 days after the
Closing Date.

         5.2.  Chargebacks, Rebates, Returns.
               -----------------------------

               (a) Chargebacks. Schwarz will be responsible for administering
                   -----------
and satisfying all chargebacks, allowances, administrative fees and similar
arrangements (collectively "Chargebacks") in each case arising with respect
                            -----------
to Products that are sold by Schwarz on or before the Closing Date. KV shall
be solely responsible for administering and satisfying all requests for
Chargebacks arising with respect to Products that are sold by KV after the
Closing Date.

               (b) Rebates.
                   -------

                   (i)   Medicaid and State Rebate Programs. Until such date
                         ----------------------------------
               that is ninety (90) days following the Closing Date (the
               "Cut-Off Date"), Schwarz shall be responsible for paying for
                ------------
               all Medicaid and state rebate programs for the Products sold
               and paid for by Medicaid or state rebate programs and for
               which a qualified invoice is issued. Schwarz shall be
               responsible for all Medicaid and state rebate reporting
               activity for Schwarz-labeled Products before and after the
               Closing Date. KV shall be responsible for paying for all
               rebates for Products sold

                                     3

<PAGE>
<PAGE>

               and paid for by Medicaid or state rebate programs, and for
               all related reporting activities, after the Cut-Off Date.
               Schwarz shall pay rebates for Schwarz-labeled Product(s)
               after the Closing and KV would reimburse Schwarz for
               post-Closing rebates paid on KV's behalf (in accordance with
               Section 5.2(d)) after the Cut-Off Date. Quarterly, on or
               --------------
               before the tenth (10th) day following the end of any calendar
               quarter in which KV has sold Schwarz-labeled Products, KV
               will provide Schwarz with the appropriate pricing information
               (i.e., average manufacturer's price and best price) related
               to the Schwarz-labeled Products sold by KV to be combined
               with Schwarz pricing information for the quarter and reported
               to the appropriate agency.

                   (ii)  Managed Care, Retail Pharmacy and Other Customer
                         ------------------------------------------------
               Rebates. After the Closing Date, Schwarz shall be responsible
               -------
               for all managed care rebates and GPO administrative fees for
               the Products sold by Schwarz and paid for by a managed care
               or retail pharmacy entity or other customer, or otherwise
               pursuant to a customer agreement and for which a qualified
               rebate invoice is issued. KV shall be responsible to pay
               rebates and GPO administrative fees for Products sold by KV
               or its Affiliates that are paid for by a managed care or
               retail pharmacy entity or otherwise pursuant to a customer
               agreement.

               (c) Returns. Any Products sold by Schwarz that are returned to
                   -------
either KV or Schwarz following the Closing Date shall be for the account of
Schwarz; provided, however, that, once the aggregate value of all such
returns accepted by KV and Schwarz after the Closing Date equals $400,000,
all returns accepted by either KV or Schwarz shall thereafter be allocated
100% for the account of KV. Schwarz or KV, as applicable, shall be entitled
for reimbursement in accordance with Section 5.2(d) for the cost of any
                                     --------------
returns that it accepts for the account of the other Party. Schwarz and KV
shall destroy such returned Products. KV shall not, and shall not cause any
of its Affiliates or any Third Party to encourage any purchaser of Products
sold by Schwarz to return such Products.

               (d) Reimbursement. KV or Schwarz, as the case may be, shall,
                   -------------
on a monthly basis, submit to the other Party a written request for any
amount for which it is entitled to reimbursement pursuant to this Section 5.2,
                                                                  -----------
together with all supporting documentation reasonably necessary to
verify such claim. The Party receiving such a request shall make payment
thereof within thirty (30) days of receipt of such documentation.

               (e) Identification. For purposes of determining whether
                   --------------
Product was sold by Schwarz or KV pursuant to this Section 5.2, Schwarz and
                                                   -----------
KV shall refer to lot numbers under which Product was sold, if available. In
case of split lots that can not be identified or attributed to Schwarz or
KV, the relevant cost or expense shall allocated pro rata between Schwarz
and KV in the same ratio as the parties' share of the split lot.

         5.3.  Promotional Materials. Schwarz shall take all commercially
               ---------------------
reasonable steps necessary or reasonably requested by KV to cease all
promotional, marketing and sales efforts in respect of the Products as of
the Closing Date, including, without limitation, removing all references to
the Products from Schwarz's (and its Affiliates') websites and destroying
all promotional, sales and marketing materials relating to the Products in
Schwarz's possession;

                                     4

<PAGE>
<PAGE>

provided, however, that Schwarz reserves the right to retain one copy of any
written materials in respect of the Products, which materials shall remain
subject to the confidentiality provisions contained herein and, provided
further, that nothing in this Section 5.3 shall apply to any activities in
                              -----------
respect of, or materials used in, the continents of Asia or Australia by
Schwarz or any of its Affiliates, including, without limitation, Schwarz
Pharma Co., Ltd. and Schwarz Pharma Philippines Inc.

         5.4.  Transitional Assistance. Schwarz shall use commercially
               -----------------------
reasonable efforts to: (a) except as otherwise instructed by KV, notify
customers for the Products of the transfer of sales of the Products to KV;
provided that KV shall have the right to approve any written communication
for such purpose; and (b) maintain Schwarz's medical inquiry support for
each of the Products for forty-five (45) days after the Closing and refer
persons who call with medical inquiries regarding any Product to KV or as
otherwise designated by KV.

         5.5.  Disclosure of Know-How and Regulatory Materials. To the
               -----------------------------------------------
extent not heretofore provided or disclosed, at or promptly following the
Closing, Schwarz shall provide or disclose to KV (i) all of the materials
and information constituting the Know-How and (ii) any written
correspondence between Schwarz and the FDA and any other reports, filings or
other materials furnished by Schwarz to the FDA in respect of the Products
during the past three (3) years.

         5.6.  Supply Obligation.
               -----------------

               (a) SPM shall, pursuant to a written purchase order from KV
received by SPM no later than twenty (20) days following the Closing Date,
supply to KV the amounts of the Products set forth on Schedule 3.2. Such
                                                      ------------
Products shall be supplied at the applicable prices set forth on Schedule 3.2
                                                                 ------------
and shall be delivered EXW (Incoterms 2000) SPM's facility located at
the address set forth in the first paragraph of this Agreement no later than
ninety (90) days after the date of SPM's receipt of the purchase order
therefor. Payment for Products supplied pursuant to this Section 5.6 shall
                                                         -----------
be due and payable no later than thirty (30) days after KV's receipt of
SPM's invoice therefor.

               (b) All Products supplied pursuant to this Section 5.6 shall
                                                          -----------
(i) be manufactured in accordance with cGMP, (ii) conform to the
Specifications, (iii) have at least 12 months dating and (iv) not be
adulterated within the meaning of the Act. EXCEPT AS EXPRESSLY SET FORTH IN
THIS SECTION 5.6(b), SCHWARZ MAKES NO REPRESENTATIONS OR WARRANTIES TO KV IN
     --------------
RESPECT OF ANY PRODUCTS SUPPLIED PURSUANT TO THIS SECTION 5.6 AND
                                                  -----------
SPECIFICALLY DISCLAIMS ANY STATUTORY OR IMPLIED WARRANTIES, INCLUDING ANY
WARRANTY OF MERCHANTABILITY OR FITNESS FOR A SPECIFIC PURPOSE.

         5.7.  Liability Insurance. For at least two (2) years following the
               -------------------
Closing Date, each of Schwarz and KV shall maintain in full force and effect
product liability insurance in respect of the Products in the amount of
$10,000,000 per occurrence and in the aggregate.

         5.8.  Merz Agreement. Schwarz shall issue a written termination
               --------------
notice to Merz Pharmaceuticals, LLC ("Merz") in respect of, and shall
                                      ----
thereafter terminate, that certain

                                     5

<PAGE>
<PAGE>

Framework Agreement, dated September 30, 2002, between SPM and Merz (the
"Merz Agreement") in accordance with the terms thereof promptly after the
----------------
date hereof.

         5.9.  Opti-Med Agreement. Schwarz shall cause Schwarz Pharma,
               ------------------
Inc. ("SPI") to issue a written termination notice to Opti-Med CR Labs, Inc.
("Opti-Med") in respect of, and thereafter terminate, that certain License
  --------
Agreement, dated February 7, 2001, between SPI and Opti-Med (the "Opti-Med
                                                                  --------
Agreement") in accordance with the terms thereof promptly after the date
---------
hereof. Prior to termination of the Opti-Med Agreement in accordance with
this Section 5.9, Schwarz shall ensure that SPI does not approve any Sales
     -----------
Agreement (as defined in the Opti-Med Agreement) as contemplated by the
Opti-Med Agreement.

6.       REGULATORY MATTERS.

         6.1.  ADE Reporting. SPM acknowledges its responsibility for any
               -------------
ADEs in respect of Products manufactured by SPM and shall be responsible for
any reports in respect thereof required by Applicable Laws. KV shall be
solely responsible for all ADEs and such reporting obligations in respect of
Products manufactured by KV. Schwarz shall provide oral notice to KV of any
ADE in respect of the Products promptly after becoming aware thereof and
thereafter shall furnish to KV a copy of any report to a Regulatory
Authority in respect of such ADE promptly after such report is made.

         6.2.  Notices.
               -------

               (a) Within seven (7) days after the Closing Date, both KV and
Schwarz will inform the FDA of the ownership transfer of the Products as
provided for in 21 CFR 207.

               (b) KV shall, as promptly as practicable following the Closing
Date, file the Trademark Transfer Agreement with the U.S. Patent and
Trademark Office and take such additional actions as may be necessary to
transfer the foreign Trademarks under the laws of the applicable non-U.S.
jurisdictions.

7.       REPRESENTATIONS AND WARRANTIES.

         7.1.  Representations and Warranties of KV. KV hereby represents
               ------------------------------------
and warrants to Schwarz as follows:

               (a) Organization, Qualification and Good Standing. KV is a
                   ---------------------------------------------
corporation duly organized, validly existing and in good standing under the
laws of the State of Delaware and is duly qualified to transact business in
each jurisdiction in which the failure to so qualify would reasonably be
expected to have a material adverse effect on its business, properties,
assets or condition (financial or otherwise).

               (b) Authority. KV has the corporate power and authority to
                   ---------
execute and deliver this Agreement and the other Transaction Documents to
which it is a party and to perform its obligations hereunder and thereunder
and has taken all requisite corporate action to execute and deliver this
Agreement and the other Transaction Documents to which it is a party. This
Agreement and the other Transaction Documents to which KV is a party have
been or at the Closing will be duly and validly executed and delivered by KV
and are, or upon the execution

                                     6

<PAGE>
<PAGE>

thereof will be, the legal, valid and binding obligations of KV, enforceable
against KV in accordance with their terms, subject to applicable bankruptcy,
insolvency and similar laws affecting creditors' rights generally and to
general principles of equity.

               (c) No Violation. The execution, delivery and performance by
                   ------------
KV of this Agreement and the other Transaction Documents to which it is a
party and its compliance with the terms and conditions hereof and thereof do
not and will not conflict with or result in a breach of any of the terms and
conditions of or constitute a default, with or without the passage of time,
the giving of notice or both, under: (i) any loan agreement, guaranty,
financing agreement, license, or other agreement or instrument binding or
affecting it or its property; (ii) the provisions of its certificate of
incorporation or bylaws; or (iii) any judgment, order, writ, injunction or
decree of any court or governmental or administrative authority entered
against it or by which it or any of its property is bound.

               (d) Consents. To KV's knowledge, no consent, waiver, approval,
                   --------
order, permit or authorization of, or declaration or filing with, or
notification to, any Person or governmental body is required on the part of
KV in connection with the execution and delivery of this Agreement or the
other Transaction Documents to which KV is a party or the compliance by KV
with any of the provisions hereof or thereof, other than (i) the notices
contemplated in Section 6.1 and (ii) any such permit, authorization,
                -----------
declaration, filing or notification which would not reasonably be expected
to have a material adverse effect on KV or its ability to enter into the
Transaction Documents or consummate the transactions contemplated thereby.

               (e) Litigation. There is no pending or, to the knowledge of
                   ----------
KV, threatened legal proceeding, action, arbitration or court, governmental
or administrative judgment, order or ruling that seeks to enjoin or obtain
damages in respect of the consummation of the transactions contemplated by
this Agreement or that questions the validity of this Agreement, the other
Transaction Documents to which KV is a party or any action taken or to be
taken by KV in connection with the consummation of the transactions
contemplated hereby or thereby.

               (f) Brokers. No Person has acted directly or indirectly as a
                   -------
broker, finder or financial advisor for KV in connection with the
negotiations relating to, or the transactions contemplated by, this
Agreement and no Person is entitled to any fee, commission or like payment
in respect thereof based in any way on any agreement, arrangement or
understanding made by or on behalf of KV.

EXCEPT AS EXPRESSLY SET FORTH IN THIS SECTION 7.1, KV MAKES NO
                                      -----------
REPRESENTATIONS OR WARRANTIES TO SCHWARZ AND SPECIFICALLY DISCLAIMS ANY
STATUTORY OR IMPLIED WARRANTIES, INCLUDING ANY WARRANTY OF MERCHANTABILITY
OR FITNESS FOR A SPECIFIC PURPOSE.

         7.2.  Representations and Warranties of Schwarz. Schwarz hereby
               -----------------------------------------
represents and warrants to KV as follows:

               (a) Organization, Qualification and Good Standing. SPM is a
                   ---------------------------------------------
corporation duly organized, validly existing and in good standing under the
laws of the State of Indiana and SRZ is a corporation duly organized,
validly existing and in good standing under the laws of

                                     7

<PAGE>
<PAGE>

the State of Delaware and each of SPM and SRZ is duly qualified to transact
business in each jurisdiction in which the failure to so qualify would
reasonably be expected to have a material adverse effect on its business,
properties, assets or condition (financial or otherwise).

               (b) Authority. Each of SPM and SRZ has the power and authority
                   ---------
to execute and deliver this Agreement and the other Transaction Documents to
which it is a party and to perform its obligations hereunder and thereunder
and has taken all requisite corporate action to execute and deliver this
Agreement and the other Transaction Documents to which it is a party. This
Agreement and the other Transaction Documents to which SPM or SRZ, as
applicable, is a party have been, or at the Closing will be, duly and
validly executed and delivered by SPM or SRZ, as the case may be, and are,
or upon the execution thereof will be the legal, valid and binding
obligations of SPM or SRZ, as applicable, enforceable against such party in
accordance with their terms, subject to applicable bankruptcy, insolvency
and similar laws affecting creditors' rights generally and to general
principles of equity.

               (c) No Violation. The execution, delivery and performance of
                   ------------
this Agreement and the other Transaction Documents to which SPM or SRZ is a
party and the compliance with the terms and provisions hereof and thereof by
SPM and SRZ do not and will not conflict with or result in a breach of any
of the terms or conditions of or constitute a default, with or without the
passage of time, the giving of notice or both, under: (i) any agreement,
license, document, instrument, indenture, guarantee or other agreement or
instrument binding on or affecting Schwarz or its assets; (ii) the
provisions of its charter, bylaws or similar corporate governing instruments
of SPM or SRZ, as applicable; or (iii) any order, writ, injunction or decree
of any court or governmental or administrative authority, which affects or
could affect the Products, the Know-How, the Trademarks, the Copyrights or
the performance of this Agreement or the other Transaction Documents to
which SPM or SRZ is a party by SPM or SRZ or the rights being transferred by
Schwarz hereunder and thereunder, except, in each case, as would not
reasonably be expected to have a material adverse effect on Schwarz or its
ability to enter into the Transaction Documents or to consummate the
transactions contemplated thereby.

               (d) Information and Records. Schwarz has provided to KV:
                   -----------------------
(i) a list of substantially all Third Party purchasers of each of the
Products, together with amounts purchased, by quarter, since January 1,
2002, (ii) a list of all chargeback, rebate, discount, allowance, Third
Party reimbursement or administrative fee or other agreements or
arrangements relating to the sale of each of the Products, and price
changes, including (but not limited to) any agreements for extended payment
terms or other unusual terms or conditions of sale of the Products agreed to
by Schwarz, as well as Schwarz's return policies with respect to the
Products, since January 1, 2002 and (iii) a list of ADEs. Such information
shall be considered Confidential Information subject to the terms of Section 10.
                                                                     ----------

               (e) Returns. Schwarz has provided KV information regarding the
                   -------
level of returns of each of the Products since January 1, 2002, which
information is complete and accurate in all material respects.

               (f) Certain Changes. Except as disclosed in Schedule 7.2(f),
                   ---------------                         ---------------
since October 1, 2002, Schwarz has not made any material deviation from the
ordinary and usual course of the manufacture or sale of the Products,
including selling and pricing.

                                     8

<PAGE>
<PAGE>

               (g) Financial Information. The Product Financial Information in
                   ---------------------
respect of the period from January 1, 2002 to December 31, 2002 and for the
period from January 1, 2003 to February 28, 2003 has been prepared in good
faith from the books and records of Schwarz in accordance with the standard
accounting procedures of Schwarz, consistently applied, and fairly presents,
in all material respects, the information contained therein. The Product
Financial Information in respect of the period from January 1, 2002 to
December 31, 2002 has been used in preparing the audited financial
statements of Schwarz and its Affiliates for fiscal year 2002.

               (h) Extensions; Generics. Schwarz has not developed or planned:
                   --------------------
(i) any unlaunched extension or improvement of any Product for sale in North
America, or (ii) a generic alternative product to any Product.

               (i) Litigation. There are no pending or, to the knowledge of
                   ----------
Schwarz, threatened product liability or other claims, actions,
arbitrations, administrative or other proceedings affecting Schwarz, the
Products, the Know-How, the Trademarks or the Copyrights or which could
materially and adversely affect either: (i) the transactions contemplated by
this Agreement or the other Transaction Documents to which SPM or SRZ is a
party or (ii) the manufacture, packaging, use, offer for sale, sale or
distribution of the Products. Neither Schwarz nor its insurer has made any
payment with respect to any product liability claims relating to the
Products under any insurance policy (including self-insurance).

               (j) Inventory. All Products included in the Inventory were
                   ---------
manufactured in accordance with cGMP, meet the Specifications, have a
remaining dating of not less than 12 months, and are not adulterated within
the meaning of the Act.

               (k) No Conflicting Rights. Except as contemplated by those
                   ---------------------
certain agreements between Schwarz and its Affiliates and Opti-Med CR Labs,
Inc. which are disclosed on Schedule 7.2(l), Schwarz owns and has not sold,
                            ---------------
transferred, sublicensed, pledged, encumbered or granted any rights or
interest in or to the Know-How, the Trademarks, the Copyrights or the
Products to any Third Party inconsistent with the provisions of this
Agreement. The rights of Schwarz's Affiliates to use the Trademarks are
limited to the manufacture, use and sale of the Products by such Affiliates
in the continents of Asia, Australia and in Denmark, Estonia, Iceland,
Latvia, Lithuania, Norway or Sweden. SPI has not heretofore approved any
Sales Agreements (as defined in the Opti-Med Agreement) as contemplated by
the Opti-Med Agreement.

               (l) Contracts. Set forth on Schedule 7.2(l) hereto is a list of
                   ---------               ---------------
(i) each written or other binding agreement, commitment or understanding
with any Third Party pertaining to the manufacture, packaging, labeling,
filling, marketing, sale or distribution of the Products, other than
purchase orders entered into by Schwarz in the ordinary course of business
and (ii) each agreement between Schwarz and any Third Party pursuant to
which Schwarz is obligated to sell any Product or to pay or credit
reimbursements, rebates, chargebacks, discounts, refunds or other
arrangements relating to the sale of a Product to Third Party buyers or
users of any Product (collectively, the "Contracts"). Schwarz has not
                                        -----------
experienced any material adverse change in the existence or terms of the
Contracts with respect to the Products since January 1, 2002.

                                     9

<PAGE>
<PAGE>

               (m) Compliance With Laws. Except as set forth on
                   --------------------
Schedule 7.2(m), no Regulatory Approvals have been obtained with respect to
---------------
the manufacture, marketing, promotion, sale or distribution of the Products.
To its knowledge, Schwarz has complied in all material respects with all
other Applicable Laws in connection with the development, manufacture,
testing, import, export, marketing, advertising, offer for sale, sale and
distribution of the Products.

               (n) Infringement. The Trademarks are owned by Schwarz and
                   ------------
constitute the only trademarks, except for variations of the corporate name
"Schwarz", under which the Products are or have been sold by Schwarz.
Schwarz has no knowledge and has received no written allegation or claim
from any Third Party that any Product, Know-How, Trademarks or other
intellectual property related to the Products infringes upon the
intellectual property rights of any other Person, and Schwarz has the right
to sell and transfer the same to KV, as provided hereunder.

               (o) Brokers. No Person has acted directly or indirectly as a
                   -------
broker, finder or financial advisor for Schwarz in connection with the
negotiations relating to, or the transactions contemplated by, this
Agreement and no Person is entitled to any fee, commission or like payment
in respect thereof based in any way on any agreement, arrangement or
understanding made by or on behalf of Schwarz.

EXCEPT AS EXPRESSLY SET FORTH IN THIS SECTION 7.2, SCHWARZ MAKES NO
                                      -----------
REPRESENTATIONS OR WARRANTIES TO KV AND SPECIFICALLY DISCLAIMS ANY STATUTORY
OR IMPLIED WARRANTIES, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS
FOR A SPECIFIC PURPOSE.

         7.3.  Survival of Representations and Warranties. The respective
               ------------------------------------------
representations and warranties of the Parties hereto shall survive the
Closing until June 30, 2004.

8.       NON-COMPETITION.

         8.1.  Schwarz agrees that for the five (5) year period following the
Closing Date, Schwarz will not offer for sale, sell or distribute or assist or
enable any Affiliate to offer for sale, sell or distribute or license,
directly or indirectly, in or in respect of North America (i) any generic
version of any Products or (ii) any Competing Product; provided, however,
                                                       --------  -------
that nothing contained herein shall preclude Schwarz or its Affiliates from
(i) any activity in respect of Ferro Sanol, (ii) licensing the Niferex
trademark to OY Verman, AB for use in Denmark, Estonia, Finland, Iceland,
Latvia, Lithuania, Norway and Sweden, but not outside such countries, (iii)
subject to Section 5.8, supplying any of the Products to Merz, in accordance
           -----------
with Schwarz's obligations under the Merz Agreement, (iv) manufacturing the
Products for sale in, or the marketing, distribution or sale of the Products
solely in, the continents of Asia or Australia, it being understood that
neither Schwarz nor its Affiliates shall encourage the resale of such
Products in North America, or (v) filling the Excluded Purchase Orders.

         8.2.  In the event Schwarz or any of its Affiliates acquires a Third
Party which has filed an application for Regulatory Approval for or makes or
sells one or more product that would violate Section 8.1, Schwarz or any of its
                                             -----------
Affiliates shall be permitted to make, have made,

                                     10

<PAGE>
<PAGE>

market, use, sell and offer for sale such products, whether or not the
period specified in Section 8.1 has expired and whether or not such products
                    -----------
compete directly or indirectly with any Product; provided, however, that
Schwarz shall or shall cause its applicable Affiliate to use commercially
reasonable efforts to divest itself of such products within nine months
after the closing of such acquisition or merger.

         8.3.  Because of the immediate and irreparable damage that would be
caused to KV for which monetary damages would not be a sufficient remedy,
the Parties agree that KV will be entitled to seek specific performance,
temporary and permanent injunctive relief, and other equitable remedies
against Schwarz in the event of the breach or threatened breach of the
provisions of Section 8.1, without any obligation to post a bond or other
              -----------
security in connection therewith. This Section shall not limit any other
legal or equitable remedies that KV may have against Schwarz for violation
of the restrictions herein or otherwise under this Agreement. The
performance of this Article 8 by Schwarz's Affiliates is hereby guaranteed
                    ---------
by Schwarz.

9.       INDEMNIFICATION.

         9.1.  Indemnification by Schwarz. Schwarz shall indemnify, defend and
               --------------------------
hold harmless the KV Indemnitees from and against any and all Claims to which
the KV Indemnitees may become subject or incur, suffer or be required to pay
resulting from or arising in connection with: (a) the misrepresentation or
breach by Schwarz of any obligation, covenant, representation or warranty
contained in this Agreement or the other Transaction Documents and (b) the
Excluded Liabilities. Notwithstanding the foregoing, Schwarz shall have no
obligation under this Agreement to indemnify, defend or hold harmless the KV
Indemnitees with respect to Claims to the extent they are caused by the
willful misconduct or negligent acts or omissions of a KV Indemnitee or the
misrepresentation or breach by KV of any obligation, covenant,
representation or warranty contained in this Agreement or any other
Transaction Document to which KV is a party.

         9.2.  Indemnification by KV. KV shall indemnify, defend and hold
               ---------------------
harmless the Schwarz Indemnitees from and against any Claims which the
Schwarz Indemnitees may become subject or incur, suffer or be required to
pay resulting from or arising in connection with: (a) the misrepresentation
or breach by KV of any obligation, covenant, representation or warranty
contained in this Agreement or any other Transaction Document to which KV is
a party and (b) the Assumed Liabilities. Notwithstanding the foregoing, KV
shall have no obligation under this Agreement or any other Transaction
Document to which KV is a party to indemnify, defend or hold harmless any
Schwarz Indemnitee with respect to Claims to the extent they are caused by a
misrepresentation under or breach of any Transaction Document by Schwarz or
the willful misconduct or negligent acts or omissions of a Schwarz
Indemnitee.

         9.3.  Determination of Damages and Related Matters. In calculating any
               --------------------------------------------
amount payable to KV pursuant to Section 9.1 or payable to Schwarz pursuant to
                                 -----------
Section 9.2, Schwarz or KV, as the case may be, such amount shall be reduced
-----------
by (i) any tax benefit allowable as a result of the facts giving rise to the
claim for indemnification, and (ii) any insurance proceeds recovered.
Schwarz and KV agree that, except as specifically set forth in this
Agreement and the Schedules hereto, neither party (including its
representatives) has made or shall have liability for any representation or
warranty, express or implied, in connection with the transactions

                                     11

<PAGE>
<PAGE>

contemplated by this Agreement. ANYTHING TO THE CONTRARY HEREIN
NOTWITHSTANDING, NO PARTY SHALL BE LIABLE TO ANY OTHER PARTY FOR ANY
SPECIAL, CONSEQUENTIAL, INCIDENTAL, INDIRECT OR PUNITIVE DAMAGES OR ANY
AMOUNT ATTRIBUTABLE TO LOST PROFITS.

         9.4.  Limitation on Indemnification Liabilities. The indemnification
               -----------------------------------------
rights in favor of KV Indemnitees contained in Section 9.1 shall terminate
                                               -----------
once the dollar amount of all direct or indirect losses, liabilities,
damages and expenses (including reasonable attorneys' fees) indemnified
against under such Section reaches Five Million Dollars ($5,000,000) in the
aggregate. Any indemnity payment made pursuant to this Agreement will be
treated as an adjustment to the Purchase Price for tax purposes, unless a
determination (as defined in Section 1313 of the Code) with respect to the
indemnified party causes such payment not to constitute an adjustment to the
Purchase Price for United States federal income tax purposes.

         9.5.  Notice and Assistance. Each Party shall promptly notify the
               ---------------------
other, in writing, if it learns of any Claim related to any Product, the
Intellectual Property, any Applicable Laws or any other matter asserted or
threatened against such Party (the "Defending Party") with respect to which
                                    ---------------
it expects to seek indemnification from the other Party hereunder (an
"Indemnifiable Claim"). With respect to any Indemnifiable Claims asserted
 -------------------
against a Defending Party, the other Party shall, at no out-of-pocket
expense to it except as provided in this Article 9, reasonably cooperate
                                         ---------
with and provide such reasonable assistance to the Defending Party as such
Defending Party may reasonably request in connection with its defense
against such Indemnifiable Claim. Such reasonable assistance shall include,
but is not limited to, providing copies of all relevant documents,
correspondence and other materials that the Defending Party may reasonably
request; provided, however, that any Confidential Information so provided
shall be treated in accordance with the provisions of Article 10.
                                                      ----------

         9.6.  Conditions to Indemnification. The obligations of the
               -----------------------------
indemnifying Party under Sections 9.1 and 9.2 are conditioned upon the
                         ------------     ---
delivery of written notice to the indemnifying Party of any potential
Indemnifiable Claim within twenty (20) days after the indemnified Party
receives actual knowledge of the potential Indemnifiable Claim; however, the
failure to give notice within such twenty (20) day period shall be a defense
only to the extent the indemnifying Party is actually prejudiced thereby.

         9.7.  Indemnification Procedure for Third-Party Claims. Except as
               ------------------------------------------------
otherwise provided herein, in the event of the initiation of any legal
proceeding against an indemnified Party by a Third Party, the indemnifying
Party shall have the absolute right after the receipt of notice, at its
option and at its own expense, to be represented by counsel of its choice,
and to defend against, negotiate, settle (subject to Section 9.8) or
                                                     -----------
otherwise deal with any proceeding, claim, or demand which relates to any
loss, liability or damage indemnified against hereunder; provided, however,
                                                         --------  -------
that the indemnified Party may participate in any such proceeding with
counsel of its choice and at its expense. The parties hereto agree to
cooperate fully with each other in connection with the defense, negotiation
or settlement (subject to Section 9.8) of any such legal proceeding, claim
                          -----------
or demand. To the extent the indemnifying Party elects not to defend such
proceeding, claim or demand, and the indemnified Party defends against or
otherwise deals with any such proceeding, claim or demand, the indemnified
Party may retain counsel, at the expense of the indemnifying Party, and
control the defense of such proceeding. If the indemnifying Party elects not
to defend

                                     12

<PAGE>
<PAGE>

any such proceeding, the indemnified Party may settle, subject to
Section 9.8, such proceeding without the consent of the indemnifying Party,
-----------
and the indemnifying Party shall indemnify and hold the indemnified Party
harmless with respect to any loss, liability, claim, obligation, damage and
expense occasioned by such settlement.

         9.8.  Settlements. Neither Party may settle an Indemnifiable Claim
               -----------
without the consent of the other Party if such settlement would impose any
monetary obligation on the other Party, require the other Party to submit to
an injunction, limit the other Party's rights under this Agreement or
another Transaction Document or otherwise adversely affect the rights,
claims or interests of the other Party unless the indemnified Party is
unconditionally released from all liability in respect of such Indemnifiable
Claim.

         9.9.  Exclusive Remedy. The indemnification provided in this Article 9,
               ----------------                                       ---------
subject to the limitations set forth herein, shall be the exclusive
post-Closing remedy for damages available to any KV Indemnitee or Schwarz
Indemnitee arising out of or relating to the Transaction Documents and the
transactions contemplated thereunder.

10.      CONFIDENTIALITY.

         10.1. Nondisclosure Obligation. Prior to the date that is five (5)
               ------------------------
years after the Closing Date, neither Party shall disclose to any Third
Party or use, except as contemplated by this Agreement, any Confidential
Information (as defined below) of the other Party without the prior written
consent of the other Party. For purposes of this Agreement, "Confidential
                                                             ------------
Information" shall mean information of either Party disclosed to the other
-----------
Party that was marked "confidential," "trade secret" or a similar
designation if in tangible form, designated as confidential at time of
disclosure whether in oral or written form or which by its nature should be
understood by a reasonable party in the pharmaceutical industry to
constitute confidential information. For purposes of this Section 10.1,
                                                          ------------
Confidential Information of KV shall include the proprietary information
included in the Assets, which information shall not be subject to the
exception set forth in clause (a), below. Except as set forth in the
foregoing sentence, "Confidential Information" shall not include any
information that:

               (a) is known by the receiving Party and is not subject to an
obligation of confidentiality to a Third Party or was not obtained through a
prior disclosure by the disclosing Party;

               (b) is at the time of disclosure or thereafter becomes published
or otherwise part of the public domain without breach of this Agreement by the
receiving Party;

               (c) is subsequently disclosed to the receiving Party on a
non-confidential basis by a Third Party who has the right to make such
disclosure;

               (d) is required by law, regulation, rule, act or order of any
governmental authority or agency or administrative or self-regulatory body
with applicable authority to be disclosed by a Party, provided that notice
is promptly delivered to the other Party in order to provide an opportunity
to seek a protective order or other similar order with respect to such
information and thereafter the disclosing Party discloses to the requesting
entity only the

                                     13

<PAGE>
<PAGE>

minimum information required to be disclosed in order to comply with the
request, whether or not a protective order or other similar order is
obtained by the other Party.

         10.2. Permitted Disclosures. Notwithstanding the provisions of
               ---------------------
Section 10.1, Information may be disclosed to employees, agents,
------------
consultants, financing sources, vendors or suppliers of the recipient Party,
but only to the extent required for performance of the Transaction
Documents; provided, however, that the recipient Party obtains prior
           --------  -------
agreement from its employees, agents, consultants, financing sources,
vendors or suppliers to whom such disclosure is to be made to hold in
confidence and not make use of such Information for any purpose other than
those permitted by this Agreement and subject to the provisions of Section
                                                                   -------
10.1, and provided further, that the recipient Party shall be responsible
----
and liable for any breach of Section 10.1 to the same extent as if the acts
                             ------------
of such employees, agents, consultants, financing sources, vendors or
suppliers were the acts of the recipient Party. Each Party will use at least
the same standard of care as it uses to protect proprietary or confidential
information of its own to ensure that such employees, agents, consultants,
financing sources, vendors or suppliers do not disclose or make any
unauthorized use of the Confidential Information.

         10.3. Privileged Communications. Notwithstanding any other provision
               -------------------------
of this Article 10, it is expected that KV and Schwarz will, from time to time,
        ----------
disclose to one another privileged communications with counsel in
furtherance of this Agreement, including opinions, memoranda, letters and
other written, electronic and verbal communications. Such disclosures are
made with the understanding that they shall remain confidential and that
they are made in connection with the shared community of legal interests
existing between Schwarz and KV, including the community of legal interests
in avoiding any infringement of any patents.

11.      MISCELLANEOUS.

         11.1. Notices. All notices and other communications hereunder shall be
               -------
in writing and shall be deemed to have been duly given if delivered personally,
mailed by generally recognized next business day courier or certified or
registered mail or sent by facsimile, receipt acknowledged, to the parties
at the following addresses or at such other addresses as shall be specified
by the parties by like notice:

                     If to KV, to:

                           KV Pharmaceutical Company
                           2503 South Hanley Road
                           St. Louis, Missouri 63144-2555
                           Attention: Chief Executive Officer
                           Telefax: (314) 645-4705

                     If to Schwarz, to:

                           Schwarz Pharma Manufacturing, Inc.
                           1101 "C" Avenue West
                           Seymour, Indiana 47274
                           Attention: President
                           Telefax: (812) 523-1887

                                     14

<PAGE>
<PAGE>

         11.2. Press Releases. On or after the date of this Agreement, neither
               --------------
Party may issue a press release announcing the transactions agreed to hereunder,
except to the extent necessary to comply with applicable legal requirements.
Any such press release shall be subject to the prior review of the other
Party in accordance with any legally required timing of the release, which
approval shall not be unreasonably withheld. Subject to the foregoing, KV
shall have the right to issue the initial press release, it being understood
that such initial press release shall be issued promptly following the
Closing and that Schwarz shall issue its press release promptly following
KV's issuance of such initial press release.

         11.3. Payment of Fees and Expenses. Each Party shall pay all fees and
               ----------------------------
expenses of its respective counsel, accountants, advisors and other expenses
incurred by the Party incident to the consummation of the transactions
contemplated by this Agreement and, except as expressly provided in the
Transaction Documents, in performing its respective obligations under this
Agreement and the other Transaction Documents.

         11.4. Representation by Legal Counsel. Each Party hereto represents
               -------------------------------
that it has been represented by legal counsel in connection with this
Agreement and the other Transaction Documents and acknowledges that it has
participated in the drafting hereof and thereof. In interpreting and
applying the terms and provisions of this Agreement and the other
Transaction Documents, the Parties agree that no presumption shall exist or
be implied against the Party which drafted such terms and provisions.

         11.5. Binding Effect; No Assignment. This Agreement shall be binding
               -----------------------------
upon and inure to the benefit of the Parties and their respective successors
and assigns. No assignment of this Agreement or of any rights or obligations
hereunder may be made by any Party (by operation of law or otherwise)
without the prior written consent of each of the other Parties hereto and
any attempted assignment without such required consents shall be void.

         11.6. Choice of Law.
               -------------

               (a) This Agreement and the other Transaction Documents shall be
deemed to be made and entered into and shall be governed, construed and
enforced exclusively in accordance with the laws of the State of Delaware.
The Parties expressly agree that no conflict of laws provision shall be
applied to make the laws of any other jurisdiction applicable hereto and
waive the right to claim the application of any other laws hereto.

               (b) The parties agree for the purpose of any legal action on or
relating to this Agreement or the other Transaction Documents, the parties
expressly waive trial by jury.

               (c) Should legal action be taken by either party to enforce
the terms of this Agreement, the prevailing party shall be entitled to
recover its reasonable attorneys' fees and any related costs.

         11.7. Arbitration. Any dispute, controversy or claim arising out of
               -----------
or in connection with this Agreement shall be determined and settled by
arbitration in Chicago, Illinois, pursuant to the Rules of Arbitration then
in effect of the American Arbitration Association. Any award rendered shall
be final and conclusive upon the parties and a judgment thereon may be
entered in a court having competent jurisdiction. Any arbitration hereunder
shall (i) be submitted to an

                                     15

<PAGE>
<PAGE>

arbitration tribunal comprised of three (3) independent members
knowledgeable in the pharmaceutical industry, one of whom shall be selected
by Schwarz, one of whom shall be selected by KV, and one of whom shall be
selected by the other two arbitrators; (ii) allow for the parties to request
discovery pursuant to the rules then in effect under the Federal Rules of
Civil Procedure for a period not to exceed 90 days; and (iii) require the
award to be accompanied by findings of fact and a statement of reasons for
the decision. Each Party shall bear its own costs and expenses incurred in
any dispute which is determined and/or settled by arbitration pursuant to
this Section 11.7; provided, however, that the arbitration panel may award
     ------------
to the prevailing party the attorneys fees and expenses incurred by it in
connection with the proceedings. Except where clearly prevented by the area
in dispute, both parties agree to continue performing their respective
obligations under this Agreement while the dispute is being resolved.
Arbitration shall not prevent any Party from seeking injunctive relief where
such remedy is an appropriate form of remedy under the circumstances.

         11.8.  Entire Agreement; Amendment; Interpretation. This Agreement,
                -------------------------------------------
together with the other Transaction Documents, sets forth the complete and
final agreement between the Parties with respect to the subject matter
hereof and thereof and supersedes and terminates all prior and
contemporaneous agreements and understandings between the Parties, whether
oral or in writing. No subsequent alteration, amendment, change, waiver or
addition to this Agreement and the other Transaction Documents shall be
binding upon the Parties unless reduced to writing and signed by an
authorized officer of each Party. No understanding, agreement, promise,
representation or warranty not explicitly set forth in this Agreement or any
other Transaction Document has been relied on by any Party in deciding to
execute this Agreement or any other Transaction Document. Whenever possible,
each provision of this Agreement or any other Transaction Document and any
portion thereof shall be interpreted and applied in such a manner as to be
effective and valid under Applicable Law. If any provision of this Agreement
or any other Transaction Document (or portion thereof or thereof) is
determined by a court or other body having appropriate jurisdiction to be
invalid, illegal or incapable of being enforced, by reason of any rule of
law, administrative order, judicial decision, public policy or otherwise,
all other provisions of this Agreement or such other Transaction Document
shall, nevertheless, remain in full force and effect, and no provision (or
portion thereof) shall be deemed dependent upon any other provision (or
portion thereof), unless so expressed herein. The Parties desire and consent
that the court or other body making such determination shall, to the minimum
extent necessary to avoid any unenforceability, so reform any such provision
or portion thereof so as to render the same enforceable in accordance with
the intent herein expressed.

         11.9.  Counterparts; Facsimile Signatures; Copies. This Agreement and
                ------------------------------------------
any other Transaction Document may be executed in any number of counterparts,
each of which, when so executed and delivered, shall be deemed to be an
original, and all of which, taken together, shall constitute one and the
same instrument. Facsimile copies of original, manually signed signatures
shall be as effective as original signatures. Copies of this Agreement or
any other Transaction Document, including telefax copies, which are true
copies of the original which has been manually signed by the Parties shall
be deemed duplicate originals.

         11.10. Further Actions. Each Party agrees, subject to its rights
                ---------------
under this Agreement and each other Transaction Document, to promptly
execute, acknowledge and deliver such further

                                     16

<PAGE>
<PAGE>

instruments, and to do all other acts, as may be requested by any other
Party and necessary or appropriate to implement the terms of this Agreement
or any other Transaction Document.

                           [Signatures next page]

                                     17

<PAGE>
<PAGE>

         IN WITNESS WHEREOF, SPM, SRZ and KV have entered into this
Agreement as of the date first set forth above.

                                          KV PHARMACEUTICAL COMPANY

                                          By: /s/ Alan G. Johnson
                                             -------------------------------
                                          Name:  Alan G. Johnson
                                          Title: Senior Vice President

                                          SCHWARZ PHARMA MANUFACTURING, INC.

                                          By: /s/ Ronald Stratton
                                             -------------------------------
                                          Name:  Ronald Stratton
                                          Title: President

                                          SRZ PROPERTIES, INC.

                                          By: /s/ Jonathan Thiel
                                             -------------------------------
                                          Name:  Jonathan Thiel
                                          Title: Vice President

                                     18

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00053-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00053-of-00352.parquet"}]]